JP2016506910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506910A5 JP2016506910A5 JP2015553055A JP2015553055A JP2016506910A5 JP 2016506910 A5 JP2016506910 A5 JP 2016506910A5 JP 2015553055 A JP2015553055 A JP 2015553055A JP 2015553055 A JP2015553055 A JP 2015553055A JP 2016506910 A5 JP2016506910 A5 JP 2016506910A5
- Authority
- JP
- Japan
- Prior art keywords
- benzenesulfonamide
- pyrazol
- pyridin
- trifluoromethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-Chloro-N- (2-pyridin-2-yl-2H-pyrazol-3-yl) -benzenesulfonamide N- (2-pyridin-2-yl-2H-pyrazol-3-yl) -4-trifluoromethyl-benzenesulfonamide Chemical compound 0.000 claims 37
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- FCPHVBYUJPCCQK-UHFFFAOYSA-N 4-chloro-2-fluoro-n-[2-(4-methyl-1,3-thiazol-2-yl)pyrazol-3-yl]benzenesulfonamide Chemical compound CC1=CSC(N2C(=CC=N2)NS(=O)(=O)C=2C(=CC(Cl)=CC=2)F)=N1 FCPHVBYUJPCCQK-UHFFFAOYSA-N 0.000 claims 4
- BIQWSPWPOCTHAN-UHFFFAOYSA-N 4-cyano-n-[2-(4-methylpyridin-2-yl)pyrazol-3-yl]benzenesulfonamide;n-(2-pyridin-2-ylpyrazol-3-yl)-4-(trifluoromethylsulfanyl)benzenesulfonamide Chemical compound CC1=CC=NC(N2C(=CC=N2)NS(=O)(=O)C=2C=CC(=CC=2)C#N)=C1.C1=CC(SC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=N1 BIQWSPWPOCTHAN-UHFFFAOYSA-N 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 claims 3
- MPNSNZPKUAKLLW-UHFFFAOYSA-N 4-chloro-2-fluoro-n-(2-pyridin-2-ylpyrazol-3-yl)benzenesulfonamide Chemical compound FC1=CC(Cl)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=N1 MPNSNZPKUAKLLW-UHFFFAOYSA-N 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- GSHSUZGHWZGKHM-UHFFFAOYSA-N CCC1=CC(=C(C=C1)S(=O)(=O)N)C2=CC=NN2C3=NC(=NS3)C4CC4 Chemical compound CCC1=CC(=C(C=C1)S(=O)(=O)N)C2=CC=NN2C3=NC(=NS3)C4CC4 GSHSUZGHWZGKHM-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- UDJZSAKEYMJSOU-UHFFFAOYSA-N n-(2-pyrimidin-2-ylpyrazol-3-yl)-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=NN1C1=NC=CC=N1 UDJZSAKEYMJSOU-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000029650 alcohol withdrawal Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 1
- POKOXEDVQWICML-UHFFFAOYSA-N 3-fluoro-n-(2-pyridin-2-ylpyrazol-3-yl)-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=C(C(F)(F)F)C(F)=CC(S(=O)(=O)NC=2N(N=CC=2)C=2N=CC=CC=2)=C1 POKOXEDVQWICML-UHFFFAOYSA-N 0.000 claims 1
- ZNAJTUBTXSHDFS-UHFFFAOYSA-N 4-(trifluoromethyl)-n-[2-[2-(trifluoromethyl)pyrimidin-4-yl]pyrazol-3-yl]benzenesulfonamide Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=NC(C(F)(F)F)=N1 ZNAJTUBTXSHDFS-UHFFFAOYSA-N 0.000 claims 1
- JEMBLGCWFHBPJP-UHFFFAOYSA-N 4-chloro-n-[2-(4-methyl-1,3-thiazol-2-yl)pyrazol-3-yl]benzenesulfonamide;n-[2-(4-methyl-1,3-thiazol-2-yl)pyrazol-3-yl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CSC(N2C(=CC=N2)NS(=O)(=O)C=2C=CC(Cl)=CC=2)=N1.CC1=CSC(N2C(=CC=N2)NS(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)=N1 JEMBLGCWFHBPJP-UHFFFAOYSA-N 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XSOMDHYDYIBGDE-UHFFFAOYSA-N n-[2-(3-cyclopropyl-1,2,4-thiadiazol-5-yl)pyrazol-3-yl]-4-ethylbenzenesulfonamide Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)NC1=CC=NN1C1=NC(C2CC2)=NS1 XSOMDHYDYIBGDE-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151632 | 2013-01-17 | ||
| EP13151632.0 | 2013-01-17 | ||
| PCT/EP2014/050526 WO2014111356A1 (en) | 2013-01-17 | 2014-01-14 | Oxytocin receptor agonists for the treatment of cns diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506910A JP2016506910A (ja) | 2016-03-07 |
| JP2016506910A5 true JP2016506910A5 (enExample) | 2016-12-15 |
| JP6263553B2 JP6263553B2 (ja) | 2018-01-17 |
Family
ID=47559324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553055A Expired - Fee Related JP6263553B2 (ja) | 2013-01-17 | 2014-01-14 | Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9751870B2 (enExample) |
| EP (1) | EP2945624B1 (enExample) |
| JP (1) | JP6263553B2 (enExample) |
| KR (1) | KR20150108384A (enExample) |
| CN (1) | CN104936593B (enExample) |
| BR (1) | BR112015016323A2 (enExample) |
| CA (1) | CA2898015A1 (enExample) |
| MX (1) | MX2015008830A (enExample) |
| RU (1) | RU2664705C2 (enExample) |
| WO (1) | WO2014111356A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US10441627B2 (en) * | 2014-09-19 | 2019-10-15 | Ferring B.V. | Method of treating prader-willi syndrome |
| EP3852723B1 (en) | 2018-09-20 | 2025-11-05 | ACADIA Pharmaceuticals Inc. | Stable intranasal formulations of carbetocin |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| WO2020178441A1 (en) * | 2019-03-06 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of ngal protein |
| WO2022200568A1 (en) | 2021-03-26 | 2022-09-29 | Ot4B | Treatment of dysphagia |
| CN116459261A (zh) * | 2023-02-27 | 2023-07-21 | 徐州医科大学 | Lit-001在治疗焦虑疾病中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3014038A (en) | 1961-12-19 | Xnhxs | ||
| DE1115739B (de) | 1958-06-25 | 1961-10-26 | Ciba Geigy | Verfahren zur Herstellung von 1-Phenyl-5-(benzolsulfonamido)-pyrazolen |
| GB893755A (en) | 1958-06-25 | 1962-04-11 | Ciba Ltd | New pyrazoles and process for their manufacture |
| GB865341A (en) | 1958-07-30 | 1961-04-12 | Bayer Ag | 5-benzene-sulphonamido-1-phenyl pyrazole derivatives |
| DE1115261B (de) | 1958-07-30 | 1961-10-19 | Bayer Ag | Verfahren zur Herstellung von 1-Phenyl-5-(benzolsulfonamido)-pyrazolen |
| FR3797M (fr) * | 1963-11-05 | 1965-12-27 | Ciba Geigy | Nouvelle préparation pharmaceutique pour le traitement du diabetes mellitus. |
| US6531478B2 (en) * | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| FR2864958B1 (fr) * | 2004-01-12 | 2006-02-24 | Sanofi Synthelabo | Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique. |
| AU2008321823B2 (en) * | 2007-11-13 | 2013-03-07 | Taisho Pharmaceutical Co., Ltd. | Phenylpyrazole derivatives |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| WO2012016229A2 (en) | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
-
2014
- 2014-01-14 JP JP2015553055A patent/JP6263553B2/ja not_active Expired - Fee Related
- 2014-01-14 RU RU2015130950A patent/RU2664705C2/ru not_active IP Right Cessation
- 2014-01-14 BR BR112015016323A patent/BR112015016323A2/pt not_active Application Discontinuation
- 2014-01-14 KR KR1020157021897A patent/KR20150108384A/ko not_active Withdrawn
- 2014-01-14 CA CA2898015A patent/CA2898015A1/en not_active Abandoned
- 2014-01-14 MX MX2015008830A patent/MX2015008830A/es unknown
- 2014-01-14 CN CN201480004903.5A patent/CN104936593B/zh not_active Expired - Fee Related
- 2014-01-14 EP EP14700614.2A patent/EP2945624B1/en not_active Not-in-force
- 2014-01-14 WO PCT/EP2014/050526 patent/WO2014111356A1/en not_active Ceased
-
2015
- 2015-07-17 US US14/802,469 patent/US9751870B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506910A5 (enExample) | ||
| RU2015130950A (ru) | Агонисты рецептора окситоцина для лечения заболеваний центральной нервной системы | |
| US8153792B2 (en) | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors | |
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| CN100491374C (zh) | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 | |
| JP2020502092A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| JP2018511587A5 (enExample) | ||
| PE20191406A1 (es) | N-[4-fluoro-5-[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| JP2014508128A5 (enExample) | ||
| DK1919465T3 (en) | GSK-3 inhibitors | |
| PE20180227A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| JP2016535772A5 (enExample) | ||
| JP2017506237A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| RU2015141278A (ru) | Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента | |
| RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| CA2571361A1 (en) | Pyrimidine derivatives as 11beta-hsd1 inhibitors | |
| JP2015514073A5 (enExample) | ||
| RU2010134411A (ru) | Фенилацетамидное производное | |
| EP1711497A1 (en) | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| TW201240970A (en) | Pyrazole compounds and thiazole compounds as protein kinases inhibitors | |
| JP2010526867A5 (enExample) |